CD22 and hairy cell leukemia: The recombinant immunotoxin (IT) BL22 (Moxetumomab pasudotox/Lumoxiti) is directed against the CD22 molecule expressed by a subpopulation of B cells and is indicated for use in cases of hairy cell leukaemia (HCL) [9].